Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

How American Express Company (AXP) Dominated the Stress Tests

If you’re an investor in American Express Company (NYSE:AXP), then you have nothing to fear from the Federal Reserve’s most recent round of stress tests. Released yesterday, the iconic credit card company emerged from the central bank’s gauntlet in markedly better shape than the majority of its financial brethren. In the charts and discussion below, I examine how the company’s capital and earnings held up under the Fed’s “severely adverse” economic scenario.

American Express passed the tests with flying colors
The purpose of the stress tests is to gauge how the capital bases of the nation’s largest financial institutions hold up in the face of economic and financial turmoil. Among other things, the most extreme case assumes that real GDP declines an average of 4% this year, unemployment ratchets up to 12.1% by the second quarter of next year, and that home prices plummet by 20% over the next 24 months.

American Express Company (NYSE:AXP)As you can see in the chart below, American Express Company (NYSE:AXP)’s Tier 1 common capital ratio held up remarkably well in light of these assumptions. Starting from 12.7% at the end of last September, it bottomed out at 11.1% over the hypothetical time period from the fourth quarter of last year through the end of 2014. That equates to a 12.6% decline. By comparison, the average Tier 1 common capital ratio of the 18 institutions tested fell by a third, down to 7.4%.

Source: Federal Reserve.

With respect to net income, American Express Company (NYSE:AXP)’s hypothetical pre-tax earnings for the nine-quarter time period came in at $800 million. While this may not sound like much, it greatly exceeded the average, which came out to be a $10.8 billion loss. Bank of America Corp (NYSE:BAC) led the way down in this regard with a staggering $51.8 billion hypothetical loss. Conversely, The Bank of New York Mellon Corporation (NYSE:BK) fared the best, with $5.5 billion in earnings despite the assumed economic Armageddon.

Source: Federal Reserve.

Breaking this down a bit further, as you can see in the figure above, the vast majority of American Express Company (NYSE:AXP)’s $15.4 billion in pre-provision net revenue was consumed by loan loss provisions — that is, money set aside to cover future losses from soured credit card loans. These accounted for $14.2 billion in losses, while “other losses” ate up an additional $400 million.

And digging into the loan losses specifically, it should come as no surprise that American Express’ were largely a function of its credit card lending operations, which accounted for 75% of provisions versus the remaining 25% related to commercial and industrial loans.

Source: Federal Reserve.

At the end of the day, the stress tests are meant to do exactly what the name implies: stress you out. At least for investors in American Express Company (NYSE:AXP), however, there’s no need for this, as the company outperformed the majority of its stress-tested peers in terms of both capital erosion and earnings ability.

The article How American Express Dominated the Stress Tests originally appeared on and is written by John Maxfield.

John Maxfield has no position in any stocks mentioned. The Motley Fool recommends American Express.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!